Medlab Clinical Faces Financial Struggles, Plans ASX Re-purposing
Company Announcements

Medlab Clinical Faces Financial Struggles, Plans ASX Re-purposing

Medlab Clinical (AU:MDC) has released an update.

Medlab Clinical reports a challenging first quarter of 2025, with no cash receipts and a closing cash balance of just $15,000. The company is in talks to acquire a business and aims to re-purpose its ASX listing, with plans to initiate re-compliance following the transaction. Financial expenditures for the quarter totaled $95,000, mainly for corporate expenses.

For further insights into AU:MDC stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskMedlab Clinical Eyes ASX Re-Listing Amid Financial Update
TipRanks Australian Auto-Generated NewsdeskMedlab Clinical Posts Lower Losses, No Dividends
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App